Trial Profile
A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre, Phase 2a Study to Assess Target Engagement, Safety and Tolerability of AZD4831 in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Mitiperstat (Primary)
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Acronyms SATELLITE
- Sponsors AstraZeneca; AstraZeneca AB
- 02 Feb 2024 (https://onlinejcf.com/article/S1071-9164(23)00142-2/fulltext#:~:text=Myeloperoxidase%20inhibition%20is%20hypothesized%20to,in%20patients%20with%20HFpEF%2FHFmrEF.) MPO activity related to potentially improve heart function and clinical outcome, so added focus as TU
- 01 Jan 2024 Primary endpoint has been met. (The change from baseline in MPO activity in % after AZD4831 treatment.), as per Results published in the Journal of Cardiac Failure
- 01 Jan 2024 Results published in the Journal of Cardiac Failure